{
  "source": "PA-Notification-Stromectol.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1369-4\nProgram Prior Authorization/Notification\nMedication Stromectol® (ivermectin) oral dosage form\nP&T Approval Date 9/2021, 12/2022, 1/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nIvermectin (oral dosage form) is indicated for the treatment of parasitic infections including\nstrongyloidiasis and onchocerciasis. Ivermectin may also be used for other compendia\nsupported parasitic infections including but not limited to scabies, hookworm disease, and\nascariasis. Most infections are treated with a single weight-based dose. The U.S. Food and\nDrug Administration (FDA) has determined that currently available clinical trial data do not\ndemonstrate that ivermectin is effective against COVID-19 in humans1.\n2. Coverage Criteriaa:\nA. Stromectol (ivermectin) will be approved based on the following criterion:\n1. Diagnosis of one of the following:\na. Onchocerciasis due to nematode parasite.\nb. Pediculosis\nc. Strongyloidiasis\nd. Ascariasis\ne. Scabies (including crusted scabies)\nf. Cutaneous larva migrans (hook worm disease)\ng. Enterobiasis\nh. Filariasis\ni. Trichuriasis\nAuthorization will be issued for 1 month\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits, Medical Necessity and/or Step Therapy may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. U.S. Food and Drug Administration. Ivermectin and COVID-19. Updated April 5, 2024.\nAccessed February 2, 2025.\n2. Ivermectin [package insert]. Parsip",
    "UnitedHealthcare Services, Inc.\n1\n4. References:\n1. U.S. Food and Drug Administration. Ivermectin and COVID-19. Updated April 5, 2024.\nAccessed February 2, 2025.\n2. Ivermectin [package insert]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC.; March\n2022.\n3. Clinical Pharmacology [database online]. Ivermectin. Tampa, FL: Gold Standard, Inc.;\n2022. Updated February 10, 2025.\nProgram Prior Authorization/Notification - Stromectol (ivermectin)\nChange Control\n9/2021 New program.\n12/2022 Updated references, added state mandate footnote, revised language in\nbackground to align with updated NIH reference.\n1/2024 Annual review. Updated references.\n3/2025 Annual review. Updated references and background with FDA\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}